cnb791 ht logo promo |

Introducing the new PhysioMimix Single-Organ Higher Throughput System

Learn more
CN Bio logo CN Bio logo CN Bio logo CN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • SLAS Europe 2023

      • SOT 2023

      • WORD 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      • Doctoral Researcher (Horizon Marie Curie Doctoral Network Project)

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Leadership team

Paul-Brooks-CEO-Headshot

Dr Paul Brooks, MBA, PhD

Chief Executive Officer

Dr Brooks joined CN Bio Innovations in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.

Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.

tom-vp

Dr Tomasz Kostrzewski, PhD

VP – Science and Technology

Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was subsequently promoted to VP – Science and Technology with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.

Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.

Deepak |

Deepak Singh, BSc

VP – Sales & Marketing

Deepak Singh joins CN Bio Innovations in February 2023. He has over 30 years of commercial experience within the life science industry, leading high-performance sales, support & marketing teams in establishing new technologies and driving global scalability of products & solutions into the markets in drug discovery, bioproduction, research and diagnostics. 

Deepak was previously Head of Global Commercial at Horizon Discovery Ltd (A PerkinElmer company); VP EMEA at Pacific Biosciences; Director of EMEA Sales & Marketing at Affymetrix, and Head of UK Sales for the Genetic Analysis unit of Applied Biosystems (A Perkin-Elmer company at the time). 

Emily Drea, LLB

Emily Drea, LLB

General Counsel

Emily Drea joined CN Bio in January 2022 having worked as an in-house lawyer for 10 years at Arm Limited and more recently as Head of Legal at Pelion. Whilst at Arm, Emily held multiple roles which included supporting commercial transactions on a global level, performing numerous product counsel roles, advising on IP licensing issues, and working in collaboration with senior management on the areas of risk management and compliance. At Pelion, Emily led the legal function as it divested from Arm Limited and became its own separate legal entity. Emily is responsible for providing the legal support CN Bio needs to enable it to grow and scale. Emily also holds a Post Graduate Diploma in Intellectual Property Law and Practice from the University of Oxford.

david-scales-headshot

Dr David Scales, PhD, LLM, FRCPath

Non-executive Director

Dr Scales has broad experience in the pharmaceutical, biotech and contract research sectors in senior and non-executive roles. For more than 20 years working for large pharmaceutical companies, Dr Scales’ roles included International VP at GlaxoWellcome, overseeing development staff in the USA, UK, Italy, and Japan. During his tenure at GlaxoWellcome he represented the European pharmaceutical Industry and chaired the Safety Committee for the first two International Conferences on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

Dr Scales moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd, Charterhouse Therapeutics Ltd, and Antisoma PLC before becoming CEO of Cerogenix Ltd and then GlycoForm Ltd. In January 2013 he joined CN Bio Innovations as Chief Executive. He took on the role as Board advisor to the company in 2016 to then join as Non-Executive Director in 2018. Dr Scales initially trained as a toxicological pathologist, holds three degrees from London University and the Royal Postgraduate Medical School, and is a Fellow of the Royal College of Pathologists.

cn bio maureen coleman |

Maureen Coleman, BSc FAPSGB

Chairman

Maureen is a pharmaceutical scientist with over 40 years of experience in the life science sector in large pharma and smaller innovation-led life science companies.  She worked for many years at GSK, starting in pharmaceutical development and becoming VP of Global R&D Strategy Development. More recently, she has been working with investor-backed companies across the life science sector in CEO, Chairman and NED roles and as an Angel Investor.

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SOT 2023 March 19-23, 2023

WORD 2023 March 22, 2022